NSW Medical Research Highlighted Australia’s Collaborative Culture at the 2025 BIO Convention
NSW Medical Research shared a post on LinkedIn:
“We were privileged to be able to highlight Australia’s collaborative culture at our breakfast panel at the 2025 BIO Convention in Boston last week.
Thank you to ZERO Childhood Cancer Associate Professor Vanessa (Ness) Tyrrell, PrOSPeCT – Professor David Thomas and ProCan Technologies Professor Roger Reddel who presented to a full house, led by Anne O’Neill FTSE.
The panel explored advances in proteomics and genomics within oncology, emphasising the integration of cutting-edge technologies into clinical trials and healthcare systems. The discussion highlighted the importance of industry partnerships, government support, and collaborative approaches to improve patient outcomes, especially in pediatric and rare cancers. The active audience raised some thoughtful questions and enthusiastically networked over coffee and breakfast.
Some of the key takeaways included how:
- government backing is key to success in integrating research and healthcare.
- streamlined ethics and consent processes have enabled rapid research expansion and data sharing.
- comprehensive datasets and early adoption of advanced sequencing position Australia as a leader in pediatric oncology research.
We hope to work with you on ongoing innovation, early technology adoption, and international collaboration to maintain momentum and improve outcomes for all.”
Tracey O’Brien, Chief Cancer Officer and CEO of Cancer Institute NSW, shared this post, adding:
“Great to see NSW Cancer research and precision oncology on showcase at BIO25.”
More posts featuring NSW Medical Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023